Enanta Pharmaceuticals
ENTA
149 hedge funds and large institutions have $447M invested in Enanta Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 57 increasing their positions, 39 reducing their positions, and 15 closing their positions.
107% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 15
70.04% more ownership
Funds ownership: 0% → 70.04% (+70%)
46% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 39
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
29% more capital invested
Capital invested by funds: $347M → $447M (+$99.7M)
10% more funds holding
Funds holding: 136 → 149 (+13)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
+$8.92M |
| 2 |
State Street
Boston,
Massachusetts
|
+$6.79M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$6.65M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$5.72M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$4.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Senzar Asset Management
New York
|
-$13.5M |
| 2 |
GTC
Ghost Tree Capital
New York
|
-$6.65M |
| 3 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
-$5.9M |
| 4 |
SIM
Spark Investment Management
New York
|
-$3.66M |
| 5 |
Renaissance Technologies
New York
|
-$3.63M |
ENTA Hedge Fund Activity: Q4 2016 in Review
149 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q4 2016, worth a combined $447M — up 29% from $347M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new ENTA positions and 15 closed out — a net gain of 16 holders — while 57 added to existing stakes and 39 trimmed.
The largest buyer was First Manhattan, adding an estimated $8.92M. The largest seller was Senzar Asset Management, exiting entirely with an estimated $13.5M sold.
- 149 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q4 2016, up from 136 in Q3 2016.
- Funds reported $447M of Enanta Pharmaceuticals stock for Q4 2016, up 29% quarter-over-quarter.
- 31 funds opened new Enanta Pharmaceuticals positions in Q4 2016 and 15 closed out, a net change of +16 holders.
- The largest Enanta Pharmaceuticals buyer in Q4 2016 was First Manhattan, an estimated $8.92M added.
- The largest Enanta Pharmaceuticals seller in Q4 2016 was Senzar Asset Management, an estimated $13.5M sold.
Based on aggregated 13F filings for Q4 2016.